# **Healthcare Monthly**

January 2018





#### **Healthcare Headline Transactions**

**Target** Acquiror **Acquisition Synopsis** Optum, Inc. entered into an equity purchase agreement to acquire DaVita Medical Group for \$4.9 DaVita Medical Group, a subsidiary of DaVita, Inc. (NYSE:DVA), manages and operates medical **Healthcare Services** groups and affiliated physician networks Optum, Inc. provides information and technology-enabled health services in the United States and **Medical Group** TPG Capital, Welsh, Carson, Anderson & Stowe and Humana Inc. (NYSE:HUM) entered into a definitive agreement to acquire Kindred Healthcare, Inc. (NYSE:KND) for \$4.2 billion, a 27% premium to Kindred's 90-day volume weighted average price Kindred Healthcare, Inc. operates hospitals, nursing centers, and contract rehabilitation services Kindred Healthcare Services TPG Capital and Welsh, Carson, Anderson & Stowe are US-based private equity firms Humana Inc. operates as a health and well-being company Implied Enterprise Value Multiples: 0.6x Revenue, 9.2x EBITDA Roche Holdings, Inc. entered into a definitive merger agreement to acquire Ignyta, Inc. (NasdaqCM:RXDX) for \$1.8 billion, a 74% premium Ignyta, Inc., a precision oncology biotechnology company, engages in discovering, developing, and ıgnyta Roche commercializing molecularly targeted therapies for eradicating residual diseases BioTech / Pharma Roche Holdings, Inc., together with its subsidiaries, manufactures and sells pharmaceuticals and Stryker Corporation (NYSE:SYK) entered into a definitive merger agreement to acquire Entellus Medical, Inc. (NASDAQ:ENTL) for approximately \$620 million, a 50% premium Entellus Medical, Inc. designs, develops, and commercializes products for the minimally invasive **Medical Devices** entellus stryker treatment of patients Stryker Corporation is a manufacturer of medical devices and equipment, including reconstructive implants, neurotechnology, and spine products


Note: All premium data calculated is based on the closing market value one day prior to announcement

#### Enterprise Value / LTM Revenue







#### Enterprise Value / LTM EBITDA



## LTM Gross & EDITDA Margins





## Selected Biotech. / Pharmaceutical Transactions

Target	Acquiror	Target Description
Sucampo Pharmaceuticals, Inc.	Mallinckrodt Public Limited Company	Sucampo Pharmaceuticals, Inc. focuses on developing and marketing medicines for unmet medical needs Transaction Value: \$1,211 million Transaction Premium: 6%
Cell Design Labs, Inc.	Kite Pharma, Inc.	Cell Design Labs, Inc. develops disruptive cell-based therapies for cancer and other devastating diseases Transaction Value: \$497 million
Crown Bioscience International	JSR Corporation	Crown Bioscience International operates as a drug discovery and development solutions company Transaction Value: \$175 million upfront and \$322 million in milestones

## Selected Healthcare Services Transactions

Target	Acquiror	Target Description
PetVet Care Centers, Inc.	KKR & Co. L.P.	PetVet Care Centers, Inc. provides veterinarian services for veterinary clinics and veterinary practices
Brighter, Inc.	Cigna Corporation	Brighter, Inc. provides a platform that connects patients, providers, and payors
VitalHealth Software B.V.	Koninklijke Philips N.V.	VitalHealth Software B.V. develops cloud-based eHealth solutions for patients with chronic diseases

## Selected Life Sciences / Diagnostics Transactions

Target	Acquiror	Target Description
MedRisk, Inc.	The Carlyle Group L.P.; Carlyle Partners VI, L.P.	MedRisk, Inc. provides managed physical medicine and diagnostic imaging services
iCardiac Technologies, Inc.	eResearchTechnology, Inc.	iCardiac Technologies, Inc. provides cardiac safety, respiratory, and eCOA testing services
Fast Track Diagnostics Luxembourg S.à.r.l.	Siemens Healthcare GmbH	Fast Track Diagnostics Luxembourg S.à.r.l. designs, develops, and manufactures medical diagnostics solutions

## Selected Medical Device Transactions

Target	Acquiror	Target Description
Harpoon Medical, Inc.	Edwards Lifesciences Corporation	Harpoon Medical, Inc. develops and commercializes transcatheter devices for patients with mitral valve disease Transaction Value: \$100 million upfront and \$150 million in milestones
ImThera Medical, Inc.	LivaNova PLC	ImThera Medical, Inc. develops implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA) Transaction Value: \$78 million upfront and \$150 million in milestones
Crospon Limited	Medtronic plc	Crospon Limited develops and delivers minimally invasive medical devices for imaging and aiding surgery

## Selected TM Capital Healthcare Experience







## TM Capital's Healthcare Contacts



James I. McLaren Managing Director jmclaren@tmcapital.com (212) 809-1414



Michael S. Goldman Managing Director mgoldman@tmcapital.com (212) 809-1419



Paul R. Smolevitz Managing Director psmolevitz@tmcapital.com (212) 809-1416

